ESH

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Retrieved on: 
월요일, 10월 30, 2023
APS, VEN, TUS, KIT, Acute myeloid leukemia, SYK, European School, Treatment, MD, Conference, Doctor of Philosophy, ORR, University, FLT3, Safety, International Conference on Population and Development, MD Anderson Cancer Center, Patient, TSX, AML, Response-rate ratio, SAN, Toxic leukoencephalopathy, Pharmaceutical industry, Airline, Biology

Dr. Daver is the lead investigator on Aptose’s APTIVATE trial of tuspetinib and is recognized for significant achievements in the development of novel acute myeloid leukemia (AML) treatments, including several combination therapies.

Key Points: 
  • Dr. Daver is the lead investigator on Aptose’s APTIVATE trial of tuspetinib and is recognized for significant achievements in the development of novel acute myeloid leukemia (AML) treatments, including several combination therapies.
  • Tuspetinib (TUS) is a once-daily, oral, precision targeted kinase inhibitor that suppresses select kinases that drive the proliferation of AML.
  • “We are really pleased by our growing safety and efficacy data on tuspetinib in very difficult-to-treat AML patient populations,” said Dr. Bejar.
  • “Data from the TUS/VEN doublet gives us confidence to move tuspetinib forward into a TUS/VEN/HMA triplet for the treatment of frontline newly-diagnosed AML patients.

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Retrieved on: 
월요일, 10월 23, 2023
VEN, TUS, Acute myeloid leukemia, European School, Treatment, MD, Conference, Abstract, SAN, Venetoclax, University, FLT3, Safety, MD Anderson Cancer Center, Patient, TSX, AML, International Conference on Learning Representations, Pharmaceutical industry, Biology

Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.

Key Points: 
  • Dr. Daver is the lead investigator on Aptose’s APTIVATE trial and is recognized for significant achievements in the development of novel AML treatments, including several combination therapies.
  • Tuspetinib also is being studied in combination with venetoclax (VEN) in the APTIVATE international Phase 1/2 expansion trial in R/R AML patients.
  • Notably, tuspetinib targets venetoclax resistance mechanisms that may re-sensitize Prior-VEN failure patients to venetoclax.
  • Note that the poster presentations will include additional data not found in the abstracts.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Retrieved on: 
월요일, 10월 16, 2023
TSX, Abstract, TUS, International Conference on Emerging Infectious Diseases, Treatment, Trial of the century, Apoptosis, European School, AML, VEN, RSK, Acute myeloid leukemia, SAN, SYK, KIT, FLT3, Conference, Patient, Pharmaceutical industry, Biology

Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.

Key Points: 
  • Aptose is planning to hold a clinical update webcast on October 30, 2023, to provide additional up-to-date data on tuspetinib.
  • The posters accepted for presentation are listed below and can be viewed beginning October 29, 2023, on site at the ESH poster exhibit hall and online on the Aptose website here .
  • Notably, TUS targets VEN resistance mechanisms and appears to re-sensitize Prior-VEN failure patients to VEN.
  • We investigated the effects of TUS on key elements of the phosphokinome and apoptotic proteome in both parental and TUS-resistant AML cells.

Aptose to Present at the Cantor Global Healthcare Conference

Retrieved on: 
월요일, 9월 18, 2023
CRC, Failure, Symantec Endpoint Protection, TUS, CRH, Clinical trial, European School, AML, Patient, SAN, CR, CFO, CRi, TSX, FLT3, CRP, Conference, Venetoclax, Pharmaceutical industry

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.

Key Points: 
  • SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.
  • Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate on a panel, Targeted Therapies for AML, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference.
  • To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.
  • Aptose expects to update these data and release data on additional evaluable patients next month during the European School of Haematology (ESH) meeting in Estoril, Portugal.

Corsano Health launches Cuffless Blood Pressure

Retrieved on: 
화요일, 8월 22, 2023
Validation, EU, Marketing, DEVICE, ISO, Sleep, Health, ECG, ML, Reinier, DRS, Research, Congress, ABPM, Oxygen saturation (medicine), Vital signs, Collection, Thermoregulation, Patient, Blood pressure, AI, Heart rate, ESC, Medtech, Medical device

THE HAGUE, Netherlands, Aug. 22, 2023 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet. 

Key Points: 
  • Corsano Health is launching the company's CardioWatch EU-MDR certified patient monitoring bracelet with Cuffless Non-Invasive Blood Pressure at ESC in Amsterdam.
  • THE HAGUE, Netherlands, Aug. 22, 2023 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet.
  • The Corsano Cuffless Non-Invasive Blood Pressure algorithm has been in development since 2019 based on arterial line and ABPM data recorded from over 500 patients.
  • The Corsano Blood Pressure algorithm was validated according to ISO 81060-2:2019 and the AAMI/ESH/ISO collaboration statement "A Universal Standard for the Validation of Blood Pressure Measuring Devices" 2018.

Corsano Health launches Cuffless Blood Pressure

Retrieved on: 
화요일, 8월 22, 2023
Validation, EU, Marketing, DEVICE, ISO, Sleep, Health, ECG, ML, Reinier, DRS, Research, Congress, ABPM, Oxygen saturation (medicine), Vital signs, Collection, Thermoregulation, Patient, Blood pressure, AI, Heart rate, ESC, Medtech, Medical device

THE HAGUE, Netherlands, Aug. 22, 2023 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet. 

Key Points: 
  • Corsano Health is launching the company's CardioWatch EU-MDR certified patient monitoring bracelet with Cuffless Non-Invasive Blood Pressure at ESC in Amsterdam.
  • THE HAGUE, Netherlands, Aug. 22, 2023 /PRNewswire/ -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet.
  • The Corsano Cuffless Non-Invasive Blood Pressure algorithm has been in development since 2019 based on arterial line and ABPM data recorded from over 500 patients.
  • The Corsano Blood Pressure algorithm was validated according to ISO 81060-2:2019 and the AAMI/ESH/ISO collaboration statement "A Universal Standard for the Validation of Blood Pressure Measuring Devices" 2018.

EQS-News: APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched

Retrieved on: 
목요일, 7월 27, 2023
Saskatchewan River Sturgeon Management Board, Communication, Marketing, German Medical Association, NVL, KBV, Monheim am Rhein, AWMF, AP, EUR, EBITDA, Guideline, APPH, Growth, National Association, European Society for Medical Oncology, CPO, Association of the Scientific Medical Societies in Germany, Lithium, Birth control

Preliminary EBITDA declined to EUR -4.0 million in the first half of 2023 (H1 2022: EUR 3.2 million).

Key Points: 
  • Preliminary EBITDA declined to EUR -4.0 million in the first half of 2023 (H1 2022: EUR 3.2 million).
  • The Single Pill AP-D13 is scheduled for launch in September 2023 and AP-D19 in October 2023.
  • In order to improve profitability in the years ahead, the Company has started preparing a program to increase its operational performance and efficiency.
  • APONTIS PHARMA will publish its 2023 half-year report as planned on 10 August 2023.

ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension

Retrieved on: 
금요일, 7월 14, 2023
Health, FDA, Medical Devices, Health Technology, Pharmaceutical, Cardiology, Biotechnology, Blood pressure, CE, European Renal Association, Food, ReCore, SOLO, RDN, ERA, Journal, PMA, Patient, European Society for Medical Oncology, International Society on Hypertension in Blacks, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, International Society, Pharmaceutical industry, Medicine, Hypertension

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.

Key Points: 
  • ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) presented at their 32nd annual European Meeting on Hypertension and Cardiovascular Protection.
  • The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.
  • Current rates of treatment and control of hypertension remain suboptimal, and the ESH guidelines assist clinicians and patients in achieving the goal of better health.
  • “Recommendation of renal denervation by the recently published European Society of Hypertension (ESH) 2023 Guidelines is a significant milestone for the field of arterial hypertension management.

New European Hypertension Guidelines Pave the Way for Greater Access to High Blood Pressure Procedure

Retrieved on: 
수요일, 7월 12, 2023
Blood pressure, Exercise, International Society on Hypertension in Blacks, Diet, Chronic kidney disease, European Renal Association, Stroke, Splenic infarction, Citizens for Europe, European Society of Cardiology, RDN, ISH, ERA, Hypertension, Patient, Risk, European Society for Medical Oncology, International Society, Pharmaceutical industry

BRUSSELS, July 12, 2023 /PRNewswire/ -- Citizens of Europe at risk for heart attacks, stroke and chronic kidney disease due to uncontrolled high blood pressure will benefit from new expert treatment guidelines that recognize the benefits of renal denervation, or RDN.  

Key Points: 
  • Last month the European Society of Hypertension, or ESH, updated its treatment guidance to include RDN as a recommended treatment option for patients who need arterial hypertension management.
  • Inclusion of RDN in the treatment guidelines means patients who struggle to lower their blood pressure through diet, exercise or antihypertensive medications will now have a safe, effective adjunctive treatment option.
  • The guidelines were also endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).
  • More than 150 million Europeans currently have hypertension, according to the European Society of Cardiology, and more than 40% of them can't adequately manage their blood pressure.

Medtronic Statement on ESH Guidelines for Hypertension and Renal Denervation

Retrieved on: 
월요일, 7월 3, 2023
Health, Medical Devices, Surgery, Research, Science, Cardiology, Biotechnology, Blood pressure, GSR, RDN, European Society of Cardiology, Journal, Patient, Coronary, American Journal of Hypertension, Annual general meeting, European Association for Cardio-Thoracic Surgery, ESC, Society, Safety, Pharmaceutical industry, Medtronic, Hypertension

Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway.

Key Points: 
  • Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway.
  • The guidelines were announced at the ESH 32nd Annual Meeting and simultaneously published in the Journal of Hypertension .
  • “These new clinical guidelines in Europe reinforce the safety and effectiveness of RDN as a third pillar for difficult to control hypertension – along with lifestyle changes and medication,” said Jason Weidman, senior vice president and president of the Coronary and Renal Denervation business at Medtronic.
  • Approved for commercial use in more than 60 countries around the world, the Symplicity Spyral Renal Denervation System is currently limited to investigational use in the U.S., Japan and Canada.